JRCT ID: jRCT1080225004
Registered date:06/01/2020
CAR-T Long Term Follow Up Study
Basic Information
Recruitment status | recruiting |
---|---|
Health condition(s) or Problem(s) studied | Any patients have received a Novartis or Penn CAR-T therapy |
Date of first enrollment | 15/01/2020 |
Target sample size | 14 |
Countries of recruitment | Japan,North America,Europe,Oceania |
Study type | Other |
Intervention(s) | Previously treated CAR-T patients |
Outcome(s)
Primary Outcome | Safety Delayed AEs that are suspected to be related to previous CAR T-cell therapy |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | Not applicable |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | All patients who have received a CAR-T therapy and completed or discontinued early from a Novartis sponsored treatment protocol that utilized CAR-T cells or from any CAR-T trial sponsored by the University of Pennsylvania with which Novartis has a contractual agreement to co-develop the CAR technology. Patients who have provided informed consent for the long term follow up study prior to their study participation. |
Exclude criteria | There are no specific exclusion criteria for this study. |
Related Information
Primary Sponsor | Novartis Pharma. K.K. |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | - |
Secondary ID(s) | NCT02445222,JapicCTI-205095 |
Contact
Public contact | |
Name | Takamitsu Hirano |
Address | Toranomon Hills Mori Tower 23-1, Toranomon 1-chome Minato-ku, Tokyo 105-6333, Japan |
Telephone | +81-120-003-293 |
rinshoshiken.toroku2@novartis.com | |
Affiliation | Novartis Pharma. K.K. |
Scientific contact | |
Name | Takamitsu Hirano |
Address | Toranomon Hills Mori Tower 23-1, Toranomon 1-chome Minato-ku, Tokyo 105-6333, Japan |
Telephone | +81-120-003-293 |
rinshoshiken.toroku2@novartis.com | |
Affiliation | Novartis Pharma. K.K. |